5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United Kingdom
Cambridge University Hospitals, Cambridge The Royal Marsden Hospital - Drug Development Unit, Sutton The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton Age range
16 Years and older
Last updated January 2026